Avsola (infliximab) is a biologic medicine that helps the pain and swelling of arthritis. Avsola belongs to a class of similar medications called Anti-Tumor Necrosis Factor agents.
Avsola works by blocking Tumor Necrosis Factor (TNF), a type of signalling protein (cytokine), that is involved in systemic inflammation.
This medication may be prescribed in combination with other rheumatology medications like methotrexate.
Avsola is a type of medicine that is called a biosimilar. A biosimilar is a type of biologic medication that has been designed to be identical to an existing biologic medication, but is created using a different process.
Avsola is a biosimilar of Remicade. Both medications are known by the same generic name: infliximab. Biosimilars are often cheaper than the original medication.
Avsola is administered by intravenous infusion at specialized clinics.
Some patients start to feel better quickly with Avsola, but in others, it can take a little longer. It's important for patients starting this medication to give it some time and keep receiving infusions as-prescribed.
The manufacturer of Avsola offers a support program to Canadian patients that are prescribed the medication:Patient support program enrolment forms
Important Tests and Risks
Watch Dr. Andy Thompson, a Canadian rheumatologist, introduce Avsola in this short video:
Drug Identification Number (DIN)